Our study identifies Htr2b as a novel regulator of skeletal muscle insulin sensitivity and highlighted the therapeutic potential of targeting skeletal muscle 5-HT signaling in the treatment of obesity-related metabolic diseases. Here, HTR2B is linked to obesity due to melanocortin 4 receptor deficiency.